

2nd Global Symposium on IGRAs

Putting Interferon-gamma
Release Assays into Practice

May 30 – June 1, 2009
Dubrovnik, Croatia

Presenting practical experience gained using IGRAs for detecting TB infection, the latest clinical information on IGRAs, and new concepts in TB latency and the risk of disease progression.



Welcome

- 14.00–14.05 **Antonino Catanzaro** MD. University of California San Diego, USA
- 14.05–14.10 **Giovanni Migliori** MD. WHO Collaborating Centre for TB and Lung Diseases, Italy
- 14.10–14.15 **Luca Richeldi** MD PhD. University of Modena and Reggio Emilia, Italy

Session 1 Biology of Tuberculosis: Busting Dogmas

14.15–16.00 Keynote Addresses

- 14.15–15.00 **Shreemanta Parida** MD. Max Planck Institute for Infection Biology, Germany
Closing the gaps in our understanding of the pathogenesis tuberculosis
- 15.00–15.45 **David Lewinsohn** MD PhD. Oregon Health and Science University, USA
Natural history of TB

15.45–16.00 Discussion

16.00–16.15 Coffee Break

16.15–18.00 Selected Abstracts

- 16.15–16.30 **Morten Ruhwald**, J Petersen, K Kofoed, H Nakaoka, L Cuevas, L Lawson, S Squire, J Eugen-Olsen, P Ravn
Improving T-cell assays for the diagnosis of active and latent TB infection using IP-10

- 16.30–16.45 **Novel Chegou**, G Black, P van Helden, G Walzl
Differentiate active TB from latent TB infection: preliminary report
- 16.45–17.00 **Delia Goletti**, O Butera, V Vanini, T Ottenhof, E Girardi
New tools to discriminate active tuberculosis disease from LTBI
- 17.00–17.15 **Cynthia Chee**, K KhinMar, S Gan, T Barkham, C Koh, Y Wang
Use of QuantiFERON-TB Gold in monitoring treatment
- 17.15–17.30 **Madhukar Pai**, R Joshi, D Gajalakshmi, M Reddy, S Kalantri
Unstable IGRA conversions and reversions in a high-incidence setting
- 17.30–17.45 **Richard van Zyl-Smit**, R Meldau, G Symons, H Khalifey, S Meldau, M Badri, L Sechi, R Dawson, E Bateman, A Zumla, K Dheda
Antigen-specific alveolar-lymphocyte IFN-gamma responses for the rapid diagnosis of pulmonary tuberculosis
- 17.45–18.00 **Alice Zwerling**, J Laurantaye, D Menzies, M Pai
T-cell IFN-gamma responses in patients treated for LTBI


18.00–18.45 Juried Poster Viewing

Posters are available for viewing in the **Mistral Section C** room.

18.45–19.30 Closing Comments

- 18.45–19.15 **Ajit Lalvani** MA MBBS DM FRCP. Imperial College, UK
Future Directions
- 19.15–19.30 **Tony Radford** DCM BSc (Hons) PhD. Cellestis, Australia
Welcome from Cellestis

Most presentations include an allocation of 5 or 10 minutes for questions



Session 2 Contact Tracing and Outbreaks

- 8.00–8.30 **Noboyuki Harada** PhD. The Research Institute of Tuberculosis, Japan
The impacts of IGRAs on contact tracings—Japanese experiences
- 8.30–9.00 **Albert Nienhaus** MD PhD MPH. BGW—Accident Insurance for the Healthcare Sector, Germany
Benefits of introducing IGRAs into contact tracings—a German perspective
- 9.00–9.20 **Discussion**

Session 3 IGRAs in Healthcare Workers

- 9.20–9.50 **Toru Mori** MD PhD. Research Institute of Tuberculosis, Japan
QuantIFERON-TB Gold in HCW screening in BCG vaccinated population
- 9.50–10.20 **Charles Daley** MD. National Jewish Health, USA
Comparison of IGRAs in HCW screening in the USA
- 10.20–10.40 **Discussion**

10.40–10.55 Coffee Break**10.55–11.25 Selected Abstracts**

- 10.55–11.10 **Lesley Scott**, P Fakir, K McCarthy, T Mosendane, A van Rie, F Venter, W Stevens
QuantIFERON-TB Gold values around the cut-off—what do they mean?
- 11.10–11.25 **Alice Zwerling**, M Behr, A Verma, T Brewer, D Menzies, M Pai
Findings from the World BCG Atlas—countries likely to benefit from the highly specific IGRAs

Session 4 IGRAs in Populations with Comorbidities

- 11.25–11.55 **Luca Richeldi** MD PhD. University of Modena and Reggio Emilia, Italy
IGRAs in the face of comorbid conditions
- 11.55–12.25 **Pernille Ravn** MD PhD. University of Hvidovre Hospital, Denmark
The usefulness of IGRAs in the presence of HIV
- 12.25–12.45 **Discussion**

12:45–13:45 Lunch**13.45–14.30 Selected Abstracts**

- 13.45–14.00 **Bolette Søborg**, M Ruhwald, M Hetland, S Jacobsen, A Andersen, N Milman, V Thomsen, D Jensen, A Koch, J Wohlfahrt, P Ravn
Comparison of screening procedures for LTBI among patients with inflammatory diseases
- 14.00–14.15 **Filippo Bartalesi**, D Goletti, A Cavallo, L Attala, G Fiori, F Li Gobbi, A Mantella, M Benucci, M Maticci Cerinic, E Girardi, A Bartoloni
LTBI treatment in subjects with autoimmune diseases and T-cell interferon-gamma responses
- 14.15–14.30 **Dario Ponce de Leon**, E Acevedo, S Alvizuri
Comparison of IGRAs with TST for the detection of LTBI in RA patients in a TB endemic population

Session 5 Applications of IGRAs

- 14.30–15.00 **Masae Kawamura** MD. San Francisco Dept of Public Health, USA
Overcoming obstacles to successful applications of IGRAs
- 15.00–15.30 **Ibrahim Abubakar** MBBS MPH. Health Protection Agency, UK
Implementing IGRAs in the UK—constraints and opportunities
- 15.30–15.45 **Discussion**

15.45–16.15 Coffee Break**Session 6 Longitudinal Studies—PPV and NPV of IGRAs**

- 16.15–16.45 **Hassan Mahomed** MD. University of Cape Town, South Africa
Predictive value of TST vs QFT in adolescents in a high burden setting
- 16.45–17.15 **Maximilian Aichelburg** Vienna Medical School, Austria
Progression in HIV positive
- 17.15–17.45 **Roland Diel** MD PhD. University of Dusseldorf, Germany
Predictive value of Interferon-gamma Release Assays—a snapshot June 2009

17.45–18.20 Selected Abstract

- 17.45–18.00 **Sandra Kik**, W Franken, M Mensen, M Kamphorst-Roemer, F Cobelens, S Arend, M Borgdorff, S Verver
Predicting tuberculosis by IGRA among foreign-born contacts
- 18.00–18.20 **Discussion**

18.20–19.15 Late Breaker Poster Viewing

Posters are available for viewing in the **Mistral Section C** room.

20.00–20.30 Symposium Dinner and Presentation

- Richard O'Brien** MD. FIND, Switzerland
Introduction
- John Sbarbaro** MD MPH FCCP. University of Colorado Health Sciences Center, USA
Is there a role for TST?



Session 7 IGRAs in children

8.00–8.30 **Deborah Lewinsohn** MD. Oregon Health and Science University, USA
IGRAs in children

8.30–9.00 Selected Abstract

8.30–8.45 **Kazue Higuchi**, S Kondo, M Wada, S Hayashi, G Ootsuka, N Sakamoto, N Harada
Contact investigation in a primary school using IGRAs

8.45–9.00 **Discussion**

Session 8 Economic Issues

9.00–9.30 **Akiko Kowada** MD PhD. Katsushika City Public Health Centre, Japan
Cost effectiveness of IGRAs in Japan

9.30–10.00 **Masae Kawamura** MD. San Francisco Dept of Public Health, USA
Tuberculosis screening of contacts and HCWs in San Francisco

10.00–10.20 **Discussion**

10.20–10.50 Coffee Break

Session 9 Guidelines

10.50–11.20 **Madhukar Pai** MD PhD. McGill University, Canada
Guidelines on IGRAs: concordant or discordant?

11.20–11.50 **Kenneth Castro** MD. Centers for Disease Control and Prevention, USA
Jean-Pierre Zellweger MD. University of Lausanne, Switzerland
Roland Diel MD PhD. University of Dusseldorf, Germany
Madhukar Pai MD PhD. McGill University, Canada
Toru Mori MD PhD. Research Institute of Tuberculosis, Japan
Luca Richeldi MD PhD. University of Modena and Reggio Emilia, Italy
Panel discussion of guidelines of various countries

11.50–12.20 **Christian Lienhardt** MD PhD. Institut de Recherche pour le Développement, France
A global perspective of how IGRAs can be used

12.20–12.30 Closing Remarks

Antonino Catanzaro MD. University of California San Diego, USA

Luca Richeldi MD PhD. University of Modena and Reggio Emilia, Italy

12.30– **Lunch**

Scientific Organising Committee

Andrew Vernon MD. CDC, Division of Tuberculosis Elimination, USA

David Lewinsohn MD PhD. Oregon Health and Science University, USA

Madhukar Pai MD PhD. McGill University, Canada

Peter Davies BM BCh DM FRCP. Cardiothoracic Centre, UK

Philippe Lagrange PhD. Assistance Publique-Hôpitaux de Paris, France

Richard O'Brien MD. FIND, Switzerland

Abstract Reviewing Committee

Andrew Vernon MD. CDC, Division of Tuberculosis Elimination, USA

Christian Lienhardt MD PhD. Institut de Recherche pour le Développement, France

Jean-Pierre Zellweger MD. University of Lausanne, Switzerland

Richard O'Brien MD. FIND Diagnostics, Switzerland

Giovanni Migliori MD. WHO Collaborating Centre for TB and Lung Diseases, Italy

Co-Chairs

Antonino Catanzaro MD. University of California San Diego, USA

Luca Richeldi MD PhD. University of Modena and Reggio Emilia, Italy

More information www.igrasymposium.com

Proudly sponsored by



